AI Article Synopsis
- BRCA-associated protein-1 (BAP1) is linked to mutations in various cancers, prompting the development of targeted therapies for these mutations.
- Some of these therapies are currently undergoing clinical trials, showing a practical approach to treating BAP1-related cancers.
- Despite this progress, many of the missense mutations in BAP1 remain uncharacterized, making it difficult to effectively stratify patients for treatment.
Article Abstract
BRCA-associated protein-1 (BAP1) is mutated in several cancers and a few therapies targeting BAP1 loss-of-function mutations have been proposed, some of them being already tested in clinical trials. However, most of the missense mutations have not been functionally characterized, although such information is essential for successful patient stratification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.trecan.2019.09.006 | DOI Listing |
Publication Analysis
Top Keywords
missense mutations
8
bap1 missense
4
mutations cancer
4
cancer friend
4
friend foe?
4
foe? brca-associated
4
brca-associated protein-1
4
protein-1 bap1
4
bap1 mutated
4
mutated cancers
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!